Your browser doesn't support javascript.
loading
Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter Study.
Blesl, Andreas; Wurm, Philipp; Waschina, Silvio; Gröchenig, Hans Peter; Novacek, Gottfried; Primas, Christian; Reinisch, Walter; Kutschera, Maximilian; Illiasch, Constanze; Hennlich, Barbara; Steiner, Pius; Koch, Robert; Tillinger, Wolfgang; Haas, Thomas; Reicht, Gerhard; Mayer, Andreas; Ludwiczek, Othmar; Miehsler, Wolfgang; Steidl, Karin; Binder, Lukas; Reider, Simon; Watschinger, Christina; Fürst, Stefan; Kump, Patrizia; Moschen, Alexander; Aden, Konrad; Gorkiewicz, Gregor; Högenauer, Christoph.
Afiliação
  • Blesl A; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
  • Wurm P; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
  • Waschina S; Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Gröchenig HP; Christian-Albrechts-University Kiel, Institute for Human Nutrition and Food Science, Nutriinformatics, Kiel, Germany.
  • Novacek G; Brothers of Saint John of God Hospital, St. Veit an der Glan, Austria.
  • Primas C; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Kutschera M; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Illiasch C; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Hennlich B; Hospital Landstraße, Vienna, Austria.
  • Steiner P; Hospital Landstraße, Vienna, Austria.
  • Koch R; Hospital Wels-Grieskirchen, Wels, Austria.
  • Tillinger W; Medical University of Innsbruck, Innsbruck, Austria.
  • Haas T; Franziskus Hospital, Vienna, Austria.
  • Reicht G; Darmpraxis, Salzburg, Austria.
  • Mayer A; Brothers of Saint John of God Hospital, Graz, Austria.
  • Ludwiczek O; University Hospital, St.Pölten, Austria.
  • Miehsler W; Hospital Hall, Hall, Austria.
  • Steidl K; Brothers of Saint John of God Hospital, Salzburg, Austria.
  • Binder L; Brothers of Saint John of God Hospital, St. Veit an der Glan, Austria.
  • Reider S; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
  • Watschinger C; Department of Internal Medicine 2 (Gastroenterology and Hepatology), Faculty of Medicine, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
  • Fürst S; Christian Doppler Laboratory for Mucosal Immunology, Johannes Kepler University Linz, Linz, Austria.
  • Kump P; Department of Internal Medicine 2 (Gastroenterology and Hepatology), Faculty of Medicine, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
  • Moschen A; Christian Doppler Laboratory for Mucosal Immunology, Johannes Kepler University Linz, Linz, Austria.
  • Aden K; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
  • Gorkiewicz G; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria.
  • Högenauer C; Department of Internal Medicine 2 (Gastroenterology and Hepatology), Faculty of Medicine, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
Inflamm Bowel Dis ; 30(1): 9-19, 2024 Jan 05.
Article em En | MEDLINE | ID: mdl-37463118
ABSTRACT

BACKGROUND:

Corticosteroids are used for induction of remission in patients with moderately to severely active ulcerative colitis. However, up to one-third of patients fail to this therapy. We investigated if fecal microbial composition or its metabolic capacity are associated with response to systemic corticosteroids.

METHODS:

In this prospective, multicenter study, patients with active ulcerative colitis (Lichtiger score ≥4) receiving systemic corticosteroids were eligible. Data were assessed and fecal samples collected before and after 4 weeks of treatment. Patients were divided into responders (decrease of Lichtiger Score ≥50%) and nonresponders. The fecal microbiome was assessed by the 16S rRNA gene marker and analyzed with QIIME 2. Microbial metabolic pathways were predicted using parsimonious flux balance analysis.

RESULTS:

Among 93 included patients, 69 (74%) patients responded to corticosteroids after 4 weeks. At baseline, responders could not be distinguished from nonresponders by microbial diversity and composition, except for a subgroup of biologic-naïve patients. Within 4 weeks of treatment, responders experienced changes in beta diversity with enrichment of ascribed beneficial taxa, including Blautia, Anaerostipes, and Bifidobacterium, as well as an increase in predicted butyrate synthesis. Nonresponders had only minor longitudinal taxonomic changes with a significant increase of Streptococcus salivarius and a microbial composition shifting away from responders.

CONCLUSION:

Baseline microbial diversity and composition seem to be of limited use to predict response to systemic corticosteroids in active ulcerative colitis. Response is longitudinally associated with restoration of microbial composition and its metabolic capacity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article